Why are acute ischemic stroke patients not receiving IV tPA?

Objective: To determine patient and hospital characteristics associated with not providing IV tissue plasminogen activator (tPA) to eligible patients with acute ischemic stroke (AIS) in clinical practice. Methods: We performed a retrospective cohort study of patients with AIS arriving within 2 hours of onset to hospitals participating in Get With The Guidelines–Stroke without documented contraindications to IV tPA from April 2003 through December 2011, comparing those who received tPA to those who did not. Multivariable generalized estimating equation logistic regression modeling identified factors associated with not receiving tPA. Results: Of 61,698 eligible patients with AIS presenting within 2 hours of onset (median age 73 years, 51% female, 74% non-Hispanic white, median NIH Stroke Scale score 11, interquartile range 6–18), 15,282 (25%) were not treated with tPA within 3 hours. Failure to give tPA decreased over time from 55% in 2003 to 2005 to 18% in 2010 to 2011 (p < 0.0001). After adjustment for all covariates, including stroke severity, factors associated with failure to treat included older age, female sex, nonwhite race, diabetes mellitus, prior stroke, atrial fibrillation, prosthetic heart valve, NIH Stroke Scale score <5, arrival off-hours and not via emergency medical services, longer onset-to-arrival and door-to-CT times, earlier calendar year, and arrival at rural, nonteaching, non–stroke center hospitals located in the South or Midwest. Conclusions: Overall, about one-quarter of eligible patients with AIS presenting within 2 hours of stroke onset failed to receive tPA treatment. Thrombolysis has improved dramatically over time and is strongly associated with stroke center certification. Additionally, some groups, including older patients, milder strokes, women, and minorities, may be undertreated.

[1]  Eric E. Smith,et al.  Patterns, Predictors, Variations, and Temporal Trends in Emergency Medical Service Hospital Prenotification for Acute Ischemic Stroke , 2012, Journal of the American Heart Association.

[2]  Joseph P. Broderick,et al.  Relationship of National Institutes of Health Stroke Scale to 30-Day Mortality in Medicare Beneficiaries With Acute Ischemic Stroke , 2012, Journal of the American Heart Association.

[3]  Andrew N. Brown,et al.  Utilization of Intravenous Tissue-Type Plasminogen Activator for Ischemic Stroke at Academic Medical Centers: The Influence of Ethnicity , 2001, Stroke.

[4]  G Schlaug,et al.  Why are stroke patients excluded from tPA therapy? An analysis of patient eligibility , 2001, Neurology.

[5]  Eric E. Smith,et al.  Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. , 2014, JAMA.

[6]  Geoff Cohen,et al.  Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis , 2012, The Lancet.

[7]  F. Veith,et al.  Letter by Paraskevas et al regarding article, "Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/american Stroke Association". , 2011, Stroke.

[8]  L. Lisabeth,et al.  Sex differences in the use of intravenous rt-PA thrombolysis treatment for acute ischemic stroke: a meta-analysis. , 2009, Stroke.

[9]  M. Conaway,et al.  Ninety-Day Outcome Rates of a Prospective Cohort of Consecutive Patients With Mild Ischemic Stroke , 2012, Stroke.

[10]  Li Liang,et al.  Get With the Guidelines–Stroke Is Associated With Sustained Improvement in Care for Patients Hospitalized With Acute Stroke or Transient Ischemic Attack , 2009, Circulation.

[11]  Eric E. Smith,et al.  Are Quality Improvements in the Get With The Guidelines-Stroke Program Related to Better Care or Better Data Documentation? , 2011, Circulation. Cardiovascular quality and outcomes.

[12]  Eric E. Smith,et al.  Data quality in the American Heart Association Get With The Guidelines-Stroke (GWTG-Stroke): results from a national data validation audit. , 2012, American heart journal.

[13]  Gordon H Guyatt,et al.  Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[14]  B. Ovbiagele,et al.  Sex differences in revascularization interventions after acute ischemic stroke. , 2013, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[15]  Jeffrey L Saver,et al.  Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. , 2009, Stroke.

[16]  W. Rosamond,et al.  Racial-Ethnic Disparities in Stroke Care: The American Experience A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2011, Stroke.

[17]  K. Lees,et al.  Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive , 2010, BMJ : British Medical Journal.

[18]  Geoff Cohen,et al.  The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial , 2012, The Lancet.

[19]  鮫島 浩,et al.  Population-based study からみた神経予後不良因子の検討 , 2009 .

[20]  Eric E. Smith,et al.  Comparison of Performance Achievement Award Recognition With Primary Stroke Center Certification for Acute Ischemic Stroke Care , 2013, Journal of the American Heart Association.

[21]  Eric E. Smith,et al.  Race/Ethnicity, Quality of Care, and Outcomes in Ischemic Stroke , 2010, Circulation.

[22]  K. Lee Get With the Guidelines–Stroke Is Associated With Sustained Improvement in Care for Patients Hospitalized With Acute Stroke or Transient Ischemic Attack , 2010 .

[23]  M. Kaste,et al.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.

[24]  Eric E. Smith,et al.  Quality of Care in Women With Ischemic Stroke in the GWTG Program , 2009, Stroke.

[25]  A. Demchuk,et al.  Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. , 2001 .

[26]  Mohit Sharma,et al.  The complexities of acute stroke decision-making: A survey of neurologists , 2014, Neurology.

[27]  Eric E. Smith,et al.  Temporal Trends in Patient Characteristics and Treatment With Intravenous Thrombolysis Among Acute Ischemic Stroke Patients at Get With the Guidelines–Stroke Hospitals , 2013, Circulation. Cardiovascular quality and outcomes.

[28]  M. Wintermark,et al.  Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.

[29]  P. Sandercock,et al.  Effect of Intravenous Recombinant Tissue-Type Plasminogen Activator in Patients With Mild Stroke in the Third International Stroke Trial-3: Post Hoc Analysis , 2015, Stroke.

[30]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[31]  Eric E. Smith,et al.  Poor Outcomes in Patients Who Do Not Receive Intravenous Tissue Plasminogen Activator Because of Mild or Improving Ischemic Stroke , 2005, Stroke.

[32]  Eric E. Smith,et al.  Use of Tissue-Type Plasminogen Activator Before and After Publication of the European Cooperative Acute Stroke Study III in Get With The Guidelines-Stroke , 2012, Circulation. Cardiovascular quality and outcomes.

[33]  L. Schwamm,et al.  Hospital treatment of patients with ischemic stroke or transient ischemic attack using the "Get With The Guidelines" program. , 2008, Archives of internal medicine.

[34]  Dawn Kleindorfer,et al.  Recombinant Tissue-Type Plasminogen Activator Use for Ischemic Stroke in the United States: A Doubling of Treatment Rates Over the Course of 5 Years , 2011, Stroke.

[35]  J. Montaner,et al.  The gender gap in stroke: a meta‐analysis , 2012, Acta neurologica Scandinavica.

[36]  Eric E. Smith,et al.  Clinical Policy: Use of intravenous tPA for the management of acute ischemic stroke in the emergency department. , 2013, Annals of emergency medicine.

[37]  Eric E. Smith,et al.  Predictors of Increased Intravenous Tissue Plasminogen Activator Use Among Hospitals Participating in the Massachusetts Primary Stroke Service Program , 2012, Circulation. Cardiovascular quality and outcomes.

[38]  Eric E. Smith,et al.  Representativeness of the Get With The Guidelines–Stroke Registry: Comparison of Patient and Hospital Characteristics Among Medicare Beneficiaries Hospitalized With Ischemic Stroke , 2012, Stroke.

[39]  F. Schmidt Meta-Analysis , 2008 .

[40]  S. Johnston,et al.  Why are eligible thrombolysis candidates left untreated? , 2006, American journal of preventive medicine.

[41]  Joseph P Broderick,et al.  Eligibility for Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke: A Population-Based Study , 2004, Stroke.

[42]  Atte Meretoja,et al.  Helsinki model cut stroke thrombolysis delays to 25 minutes in Melbourne in only 4 months , 2013, Neurology.

[43]  S. Cramer,et al.  Treatment With Tissue Plasminogen Activator and Inpatient Mortality Rates for Patients With Ischemic Stroke Treated in Community Hospitals , 2001, Stroke.

[44]  H. Diener,et al.  Influence of Age on Outcome From Thrombolysis in Acute Stroke: A Controlled Comparison in Patients From the Virtual International Stroke Trials Archive (VISTA) , 2010, Stroke.

[45]  H. Cloft,et al.  Racial and ethnic disparities in the use of intravenous recombinant tissue plasminogen activator and outcomes for acute ischemic stroke. , 2013, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[46]  P. Sandercock,et al.  Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials | NOVA. The University of Newcastle's Digital Repository , 2014 .